<DOC>
	<DOC>NCT02506257</DOC>
	<brief_summary>Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects</brief_summary>
	<brief_title>Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects</brief_title>
	<detailed_description>The primary objective of the study is to establish the ocular safety and tolerability, and systemic safety of 3 different concentrations of preservative-free PHMB in healthy subjects. Safety and tolerability will be compared to those of a placebo.The PHMB bioavailability in plasma will also be assessed</detailed_description>
	<mesh_term>Keratitis</mesh_term>
	<mesh_term>Acanthamoeba Keratitis</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Polyhexamethylene biguanide</mesh_term>
	<criteria>able and willing to give informed consent. man or woman of any race and 18 to 55 years of age, inclusive. Body Mass Index of 2030 kg/m2 willing and able to attend required study visits. bilateral visual acuity &gt;6/10. intraocular pressure (IOP) of 1421 mmHg. ophthalmologic examination without abnormalities. medical history without major pathology. laboratory test results without deviations from the normal range. female subjects of childbearing potential with negative urine pregnancy test and using effective contraception during the study. presence of bacterial ocular infections. presence of any concomitant ocular pathology. performing activities likely to result in an irritated conjunctiva during the study (including heavy alcohol intake, swimming in chlorinated water and heavy smoking). contact lenses wearing . ocular surface fluorescein staining score &gt;3. use of topical or systemic antibiotics, antihistamines, decongestants and nonsteroidal antiinflammatory agents as well as steroids within 7 days before screening. known or suspected allergy to biguanides or intolerance to any other ingredient of the test treatments. ocular surgery performed within 12 months before screening. participation in another clinical study in the preceding 30 days. one functional eye. pregnancy or breastfeeding. use of recreational drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>